ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings Inc (CERO)

0,1915
0,0185
(10,69%)
Beim Schlusskurs: 05 Dezember 10:00PM
0,1901
-0,0014
( -0,73% )
Nach Börsenschluss: 10:56PM

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
0,1901
Gebot
0,1901
Fragen
0,195
Volumen
8.091.868
0,171 Tagesbereich 0,206
0,0636 52-Wochen-Bereich 12,38
Handelsende
0,173
Handelsbeginn
0,182
Letzter Handelszeitpunkt
22:59:58
Durchschnittliches Volumen (3 Mio.)
69.471.408
Finanzvolumen
US$ 1.526.099
VWAP
0,188597

CERO Neueste Nachrichten

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an...

CERo Therapeutics, Inc. Provides Corporate Update

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation...

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes SOUTH SAN FRANCISCO, Calif., Sept. 25, 2024 (GLOBE...

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) --  CERo...

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation...

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.0061-3.109072375130.19620.210.155754735080.18012513CS
40.1155154.8257372650.07460.44770.06521835439960.24072664CS
120.0963102.6652452030.09380.44770.0636694714080.22428088CS
26-0.7233-79.18765053650.91341.020.0636354976630.22443068CS
52-5.0599-96.3790476195.2512.380.0636225500380.26719412CS
156-5.0599-96.3790476195.2512.380.0636225500380.26719412CS
260-5.0599-96.3790476195.2512.380.0636225500380.26719412CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
ZBAOZhibao Technology Inc
US$ 6,56
(157,25%)
1,27M
PGHLPrimega Group Holdings Ltd
US$ 1,68
(25,84%)
2,01M
RADXRadiopharm Theranostics Ltd
US$ 21,7999
(23,37%)
9,88k
DOCUDocuSign Inc
US$ 98,70
(17,95%)
1,41M
AOUTAmerican Outdoor Brands Inc
US$ 12,78
(17,25%)
29,18k
ORISOriental Rise Holdings Ltd
US$ 9,2118
(-83,55%)
2,91M
FOXXFoxx Development Holdings Inc
US$ 4,10
(-17,17%)
27,48k
ZCMDZhongchao Inc
US$ 1,20
(-16,08%)
4,26k
ENGENGlobal Corp
US$ 0,92
(-14,81%)
30,14k
SWBISmith and Wesson Brands Inc
US$ 11,80
(-13,43%)
99,32k
CDIOCardio Diagnostics Holdings Inc
US$ 0,533
(14,77%)
8,91M
SMCISuper Micro Computer Inc
US$ 41,3501
(0,51%)
6,81M
SVMHSRIVARU Holding Ltd
US$ 0,034
(-2,86%)
6,68M
ORISOriental Rise Holdings Ltd
US$ 9,2118
(-83,55%)
2,79M
SOUNSoundHound AI Inc
US$ 13,65
(2,40%)
2,48M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock